, in Immunology | www.frontiersin.org, p.541, 2018.
, in children with diffuse connective tissue diseases, Autoimmunity, 1990.
Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus, New England Journal of Medicine, vol.278, issue.10, pp.533-541, 1968. ,
DOI : 10.1056/NEJM196803072781004
,
anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis, Ann Rheum Dis, vol.62, issue.6, pp.556-60, 2003. ,
Autoantibodies to the Sm antigen: immunological approach to clinical aspects of systemic lupus erythematosus, J Rheumatol, vol.14, pp.188-93, 1987. ,
Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy, PLOS ONE, vol.15, issue.2, 2015. ,
DOI : 10.1371/journal.pone.0140441.s004
Antinucleosome in systemic lupus erythematosus. A study in a Brazilian population, Clinical Rheumatology, vol.18, issue.3, pp.553-559, 2012. ,
DOI : 10.1177/0961203308096255
Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis, Autoimmunity Reviews, vol.12, issue.2, pp.97-106, 2012. ,
DOI : 10.1016/j.autrev.2012.07.002
Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients, Clin Exp Rheumatol, vol.24, issue.1, pp.51-59, 2006. ,
Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: Effects of disease progression and lipopolysaccharide administration, 6<1320::AID-ART224>3.0.CO, pp.1320-1350, 2001. ,
DOI : 10.1038/33169
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus, 1<76::AID-ANR10>3.0.CO, pp.76-8410, 2000. ,
DOI : 10.1002/art.1780150206
Simultaneous Positivity for Anti-DNA, Anti-Nucleosome and Anti-Histone Antibodies is a Marker for More Severe Lupus Nephritis, Journal of Clinical Immunology, vol.349, issue.16, pp.378-87, 2013. ,
DOI : 10.1056/NEJMoa021933
PREVALENCE AND CLINICAL SIGNIFICANCE OF ANTIBODIES TO RIBONUCLEOPROTEINS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN MALAYSIA, Rheumatology, vol.35, issue.2, pp.129-161, 1996. ,
DOI : 10.1093/rheumatology/35.2.129
Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-Sm and anti-RNP antibody tests, Arthritis Care & Research, vol.11, issue.Suppl, pp.1030-1074, 2004. ,
DOI : 10.1191/0961203302lu158oa
What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3, Clin Exp Rheumatol, vol.35, issue.4, pp.598-606, 2017. ,
Reactivities to the Sm Autoantigenic Complex and the Synthetic SmD1-aa83???119 Peptide in Systemic Lupus Erythematosus and other Autoimmune Diseases, Journal of Autoimmunity, vol.17, issue.4, pp.347-540545, 2001. ,
DOI : 10.1006/jaut.2001.0545
Anti-Sm is associated with the early poor outcome of lupus nephritis, International Journal of Rheumatic Diseases, vol.30, issue.7, pp.897-902, 2016. ,
DOI : 10.1007/BF02231577
Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus, Rheumatology, vol.15, issue.1, pp.405-417, 2015. ,
DOI : 10.1186/ar4189
Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens, Clin Exp Immunol, vol.76, issue.2, pp.172-179, 1989. ,
Survival impact of autoantibodies in systemic lupus erythematosus, J Rheumatol, vol.21, issue.2, pp.224-232, 1994. ,
Autoantibody Determination in the Diagnosis of Systemic Lupus Erythematosus, Scandinavian Journal of Immunology, vol.332, issue.3, pp.227-262, 2006. ,
DOI : 10.1097/01.smj.0000171073.07875.c5
Drug-induced lupus erythematosus, Archives of Dermatological Research, vol.167, issue.Supplement, pp.99-105, 2009. ,
DOI : 10.4049/jimmunol.167.12.6821
Antihistone antibodies in systemic lupus erythematosus, J Rheumatol, vol.14, pp.118-144, 1987. ,
Anti???histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus, Journal of Clinical Laboratory Analysis, vol.42, issue.4, pp.271-278, 2008. ,
DOI : 10.1172/JCI105574
Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level, Rheumatology, vol.45, issue.10, pp.1317-1326, 2006. ,
DOI : 10.1093/rheumatology/kel227
Biologic therapies in psoriasis: A new therapeutic approach, Autoimmunity Reviews, vol.6, issue.8, pp.515-524, 2007. ,
DOI : 10.1016/j.autrev.2006.12.002
Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus, Rheum Dis Clin North Am, vol.18, issue.2, pp.337-58, 1992. ,
Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations, Clinical Rheumatology, vol.54, issue.3, pp.261-266, 1996. ,
DOI : 10.1002/art.1780360219
Key autoantigens in SLE, Rheumatology, vol.44, issue.8, pp.975-82, 2005. ,
DOI : 10.3109/08916939508993358
URL : https://academic.oup.com/rheumatology/article-pdf/44/8/975/9448004/keh688.pdf
Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen, Clinical and Experimental Immunology, vol.97, issue.1, pp.209-226, 2000. ,
DOI : 10.7326/0003-4819-97-5-664
Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review, Clinical Reviews in Allergy & Immunology, vol.176, issue.Suppl 2, pp.469-76, 2017. ,
DOI : 10.1007/s00431-017-2987-8
Neonatal Lupus: Basic Research and Clinical Perspectives, Rheumatic Disease Clinics of North America, vol.31, issue.2, pp.299-313, 2005. ,
DOI : 10.1016/j.rdc.2005.01.010
The clinical spectrum of neonatal lupus, Archives of Dermatological Research, vol.40, issue.1, pp.107-117, 2009. ,
DOI : 10.7326/0003-4819-120-7-199404010-00003
Neonatal lupus: Follow-up in infants with anti -SSA/Ro antibodies and review of the literature, Autoimmunity Reviews, vol.16, issue.4, pp.427-459, 2017. ,
DOI : 10.1016/j.autrev.2017.02.010
Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents, American Journal of Obstetrics and Gynecology, vol.208, issue.1, 2013. ,
DOI : 10.1016/j.ajog.2012.09.020
Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus, Circulation, vol.126, issue.1, pp.76-82, 2012. ,
DOI : 10.1161/CIRCULATIONAHA.111.089268
Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus, Experimental and Therapeutic Medicine, vol.5, issue.6, pp.1710-1714, 2013. ,
DOI : 10.3892/etm.2013.1051
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases, Arthritis & Rheumatism, vol.39, issue.4, pp.1248-52, 2004. ,
DOI : 10.1016/S0735-1097(02)01852-1
Anti-Ro/SSA-associated corrected QT interval prolongation in adults: The role of antibody level and specificity, Arthritis Care & Research, vol.48, issue.10, pp.1463-70, 2011. ,
DOI : 10.1093/rheumatology/kep145
URL : http://onlinelibrary.wiley.com/doi/10.1002/acr.20540/pdf
Comparison of frequency of complex ventricular arrhythmias in patients Frontiers in Immunology | www.frontiersin, p.541, 2018. ,
, SSA and connective tissue disease, Am J Cardiol, vol.100, issue.6, pp.1029-1063, 2007.
Systemic Lupus Erythematosus, Complement Deficiency, and Apoptosis, Adv Immunol, vol.76, issue.01, pp.227-324, 2000. ,
DOI : 10.1016/S0065-2776(01)76021-X
The Relationship between Serum Titers of Autoantibodies to C1q and Age in the General Population and in Patients with Systemic Lupus Erythematosus, Clinical Immunology and Immunopathology, vol.67, issue.3, pp.204-213, 1993. ,
DOI : 10.1006/clin.1993.1066
High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis, Nephrology Dialysis Transplantation, vol.21, issue.11, pp.3115-3136, 2006. ,
DOI : 10.1093/ndt/gfl436
IgG and IgA autoantibodies to C1q in systemic and renal diseases, Clin Exp Rheumatol, vol.10, issue.1, pp.19-23, 1992. ,
,
, Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance, Ann N Y Acad Sci, vol.1050, pp.193-200, 2005.
IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus, J Rheumatol, vol.18, issue.2, pp.230-234, 1991. ,
Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus, Rheumatology, vol.36, issue.1, pp.32-39, 1997. ,
DOI : 10.1093/rheumatology/36.1.32
Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis, American Journal of Kidney Diseases, vol.37, issue.3, pp.490-498, 2001. ,
DOI : 10.1053/ajkd.2001.22071
Anti-C1q antibodies in systemic lupus erythematosus, Lupus, vol.48, issue.1, pp.42-51, 2015. ,
DOI : 10.1006/clin.1993.1066
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus, American Journal of Kidney Diseases, vol.26, issue.4, pp.595-601, 1995. ,
DOI : 10.1016/0272-6386(95)90595-2
Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus., Annals of the Rheumatic Diseases, vol.52, issue.12, pp.851-857, 1993. ,
DOI : 10.1136/ard.52.12.851
Autoantibodies against C1q: view on clinical relevance and pathogenic roles, Clinical and Experimental Immunology, vol.11, issue.1, 1999. ,
DOI : 10.1007/BF02918613
No lupus nephritis in the absence of antiC1q autoantibodies?, Nephrology Dialysis Transplantation, vol.17, issue.12, pp.2041-2044, 2002. ,
DOI : 10.1093/ndt/17.12.2041
The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-Seven Patients, Arthritis & Rheumatology, vol.73, issue.2, pp.527-561, 2015. ,
DOI : 10.1016/0091-6749(84)90518-9
Clinical and serologic associations of the antiribosomal P protein antibody, Arthritis & Rheumatism, vol.81, issue.8, pp.981-986, 1986. ,
DOI : 10.1042/bj1230865
Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays, Journal of Autoimmunity, vol.19, issue.1-2, pp.71-78, 2002. ,
DOI : 10.1006/jaut.2002.0595
Neuropsychiatric features of systemic lupus erythematosus, Autoimmunity Reviews, vol.4, issue.6, pp.329-373, 2005. ,
DOI : 10.1016/j.autrev.2005.01.008
Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?, Lupus, vol.22, issue.8, pp.571-576, 2005. ,
DOI : 10.1093/rheumatology/41.12.1357
Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease, J Rheumatol, vol.18, issue.11, pp.1681-1685, 1991. ,
Autoantibodies to the ribosomal P proteins in systemic lupus erythematosus, Clinical and Experimental Medicine, vol.6, issue.2, pp.49-52, 2006. ,
DOI : 10.1007/s10238-006-0094-7
Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus, Clinical Rheumatology, vol.27, issue.2, pp.703-710, 2018. ,
DOI : 10.1002/jcla.21543
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups, Arthritis & Rheumatism, vol.52, issue.9, pp.2774-82, 2005. ,
DOI : 10.7326/0003-4819-128-9-199805010-00006
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, 7<1309::AID-ANR1>3.0.CO, pp.1309-1320, 1999. ,
DOI : 10.1191/096120398678919624
The relevance of ???non-criteria??? clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features, Autoimmunity Reviews, vol.14, issue.5, pp.401-415, 2015. ,
DOI : 10.1016/j.autrev.2015.01.002
High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus, Archives of Internal Medicine, vol.164, issue.1, pp.77-82, 2004. ,
DOI : 10.1001/archinte.164.1.77
URL : http://archinte.jamanetwork.com/data/journals/intemed/5469/ioi20852.pdf
Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus, The Journal of Rheumatology, vol.36, issue.6, pp.1195-1204, 2009. ,
DOI : 10.3899/jrheum.081194
Revisiting Libman???Sacks Endocarditis: A Historical Review and Update, Clinical Reviews in Allergy & Immunology, vol.82, issue.2-3, pp.126-156, 2009. ,
DOI : 10.1590/S0066-782X2004000400009
Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: Meta-Analysis of Echocardiographic Studies, Circulation, vol.124, issue.2, pp.215-239, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.111.028522
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort, Lupus, vol.22, issue.13, pp.170-175, 2000. ,
DOI : 10.1016/0167-5273(90)90294-F
Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis, Autoimmunity Reviews, vol.16, issue.6, pp.576-86, 2017. ,
DOI : 10.1016/j.autrev.2017.04.003
GAPSS: the Global Anti-Phospholipid Syndrome Score, Rheumatology, vol.39, issue.9, pp.1397-403, 2013. ,
DOI : 10.3899/jrheum.120073
URL : https://academic.oup.com/rheumatology/article-pdf/52/8/1397/5065260/kes388.pdf
Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review, Journal of the Neurological Sciences, vol.355, issue.1-2, pp.7-17, 2015. ,
DOI : 10.1016/j.jns.2015.05.034
Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases, European Journal of Neurology, vol.28, issue.2, pp.248-52, 2012. ,
DOI : 10.1007/s00296-008-0611-y
Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis, Journal of Neurology, vol.417, issue.1???2, pp.2293-304, 2015. ,
DOI : 10.1016/j.cca.2012.12.008
Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder, Journal of the Neurological Sciences, vol.348, issue.1-2, pp.132-137, 2015. ,
DOI : 10.1016/j.jns.2014.11.020
Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease, Journal of Neuroimmunology, vol.289, pp.8-11, 2015. ,
DOI : 10.1016/j.jneuroim.2015.10.007
Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica, Neuroimmunomodulation, vol.66, issue.2, pp.96-102, 2012. ,
DOI : 10.1002/ana.21802
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj??gren's syndrome, Annals of the Rheumatic Diseases, vol.46, issue.1, pp.9-16, 2016. ,
DOI : 10.3109/08916934.2012.732131
Immunoreactivity to Nuclear Antigens in Systemic Lupus Erythematosus with or without Nephritis, and in Other Connective Tissue Diseases, with Particular Reference to the RNA-Protein Antigen, International Archives of Allergy and Immunology, vol.53, issue.3, pp.279-89, 1977. ,
DOI : 10.1159/000231763
Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases, Clin Exp Rheumatol, vol.10, issue.3, pp.255-61, 1992. ,
Immunological detection of nucleic acids and antibodies to nucleic acids and nuclear antigens by counterimmunoelectrophoresis, Clin Exp Immunol, vol.17, issue.1, pp.209-227, 1974. ,
Prediction of Sj??gren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling, Arthritis & Rheumatology, vol.69, issue.9, pp.2427-2463, 2015. ,
DOI : 10.1136/ard.2009.110619
Clinical evolution, and morbidity and mortalityof primary Sj??gren's syndrome, Seminars in Arthritis and Rheumatism, vol.29, issue.5, pp.296-304, 2000. ,
DOI : 10.1016/S0049-0172(00)80016-5
Primary Sj??gren Syndrome in Han Chinese, Medicine, vol.94, issue.16, pp.667-677, 2015. ,
DOI : 10.1097/MD.0000000000000667
Immunological profile in primary Sj??gren syndrome, Autoimmunity Reviews, vol.9, issue.9, pp.595-604, 2010. ,
DOI : 10.1016/j.autrev.2010.05.004
Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sj??gren's syndrome, Clinical Rheumatology, vol.362, issue.Suppl, pp.341-347, 2006. ,
DOI : 10.1097/00005792-198207000-00004
The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sj??gren's syndrome, Annals of the Rheumatic Diseases, vol.46, issue.8, pp.1557-61, 2015. ,
DOI : 10.1002/art.10407
Anti-SSA/SSB-negative Sj??gren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution, Autoimmunity Reviews, vol.14, issue.11, pp.1019-1041, 2015. ,
DOI : 10.1016/j.autrev.2015.07.002
Molecular mechanisms of congenital heart block, Experimental Cell Research, vol.325, issue.1, 2014. ,
DOI : 10.1016/j.yexcr.2014.01.003
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women, 8<1832::AID-ART320>3.0.CO, pp.1832-1837, 2001. ,
DOI : 10.1002/1529-0131(200005)43:5<1049::AID-ANR13>3.0.CO;2-X
Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block, The Journal of Experimental Medicine, vol.142, issue.1, pp.11-18, 2005. ,
DOI : 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9
URL : http://jem.rupress.org/content/jem/201/1/11.full.pdf
Subgroups of Sj??gren syndrome patients according to serological profiles, Journal of Autoimmunity, vol.39, issue.1-2, pp.15-26, 2012. ,
DOI : 10.1016/j.jaut.2012.03.001
Molecular Analysis of the Human Autoantibody Response to ??-Fodrin in Sj??gren's Syndrome Reveals Novel Apoptosis-Induced Specificity, The American Journal of Pathology, vol.165, issue.1, pp.53-61, 2004. ,
DOI : 10.1016/S0002-9440(10)63274-9
Diagnostic accuracy of anti-alpha-fodrin antibodies for primary Sj??gren's syndrome, Modern Rheumatology, vol.36, issue.9, pp.793-800, 2013. ,
DOI : 10.1111/j.1365-2222.2006.02550.x
The accuracy of the anti-??-fodrin antibody test for diagnosis of Sj??gren's syndrome: A meta-analysis, Clinical Biochemistry, vol.46, issue.15, pp.1372-1378, 2013. ,
DOI : 10.1016/j.clinbiochem.2013.04.020
Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay, Clin Exp Rheumatol, vol.21, issue.1, pp.49-56, 2003. ,
Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren's syndrome, J Rheumatol, vol.35, issue.5, pp.845-854, 2008. ,
Usefulness of IgA Anti-??-fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjogren Syndrome with Negative Anti-SSA/SSB Antibodies, The Journal of Rheumatology, vol.43, issue.10, pp.1852-1859, 2016. ,
DOI : 10.3899/jrheum.151315
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Annals of the Rheumatic Diseases, vol.62, issue.(Suppl), pp.2737-2784, 2013. ,
DOI : 10.1002/art.27580
Antinuclear antibody-negative systemic sclerosis, Seminars in Arthritis and Rheumatism, vol.44, issue.6, pp.680-686, 2015. ,
DOI : 10.1016/j.semarthrit.2014.11.006
URL : http://europepmc.org/articles/pmc4447614?pdf=render
Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database, Rheumatology, vol.68, issue.4, pp.560-567, 2013. ,
DOI : 10.1007/s00393-008-0401-7
URL : https://academic.oup.com/rheumatology/article-pdf/52/3/560/5032184/kes315.pdf
Disease-related autoantibody profile in patients with systemic sclerosis, Autoimmunity, vol.33, issue.7, pp.414-435, 2017. ,
DOI : 10.1186/s13075-015-0573-x
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR groupbased study, Clin Exp Rheumatol, vol.31, issue.2, pp.96-102, 2013. ,
Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features, Arthritis Research & Therapy, vol.13, issue.5, pp.10-3495, 1186. ,
DOI : 10.1007/s004120050219
The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis, British Journal of Dermatology, vol.133, issue.3, pp.487-95, 2008. ,
DOI : 10.7326/0003-4819-133-8-200010170-00010
Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies, Arthritis & Rheumatism, vol.43, issue.3, pp.399-412, 2003. ,
DOI : 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.11113/pdf
Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern, Rheumatology, vol.98, issue.19, pp.632-639, 2009. ,
DOI : 10.1073/pnas.191321998
URL : https://academic.oup.com/rheumatology/article-pdf/48/6/632/5064079/kep070.pdf
Scl 70 antibody???a specific marker of systemic sclerosis, British Journal of Dermatology, vol.23, issue.4, pp.393-401, 1986. ,
DOI : 10.1001/archderm.119.7.560
South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome, International Journal of Rheumatic Diseases, vol.60, issue.4, 2012. ,
DOI : 10.1002/art.24409
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database, Annals of the Rheumatic Diseases, vol.66, issue.6 ,
DOI : 10.1136/ard.2006.062901
, Ann Rheum Dis, vol.66, issue.6, pp.754-63, 2007.
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis, Arthritis & Rheumatism, vol.84, issue.5, pp.1363-73, 2003. ,
DOI : 10.1006/clin.1997.4362
Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis, 5<1074::AID-ANR18>3.0.CO, pp.1074-84, 2000. ,
DOI : 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E
Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis, Arthritis & Rheumatism, vol.35, issue.1, pp.75-83, 1994. ,
DOI : 10.1097/00005792-198403000-00003
A comparison between anti-Th/To??? and anticentromere antibody???positive systemic sclerosis patients with limited cutaneous involvement, Arthritis & Rheumatism, vol.48, issue.1, pp.203-212, 2003. ,
DOI : 10.1002/art.10760
Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA, J Rheumatol, vol.34, issue.7, pp.1528-1562, 2007. ,
Prevalence of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta-Analysis, Arthritis & Rheumatology, vol.92, issue.Suppl 1, pp.407-424, 2014. ,
DOI : 10.1097/MD.0b013e31829be125
Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma, J Rheumatol, vol.26, issue.11, pp.2489-92, 1999. ,
Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma, Arthritis Research & Therapy, vol.16, issue.1, pp.10-1186, 2014. ,
DOI : 10.1080/03009740902758875
URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar4486?site=arthritis-research.biomedcentral.com
Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening, The Journal of Rheumatology, vol.44, issue.5, pp.639-686, 2017. ,
DOI : 10.3899/jrheum.160817
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study, Annals of the Rheumatic Diseases, vol.77, issue.4, pp.10-1136, 2018. ,
DOI : 10.1136/annrheumdis-2017-211912.supp5
Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase i reactivity and nucleolar staining, Arthritis Research & Therapy, vol.13, issue.4, pp.10-3422, 1186. ,
DOI : 10.1111/j.1365-2230.2006.02092.x
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies, Arthritis & Rheumatism, vol.3, issue.9, pp.2787-95, 2010. ,
DOI : 10.1016/0167-4781(95)00171-9
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.27549/pdf
Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis., Journal of Clinical Investigation, vol.91, issue.4, pp.1399-404, 1993. ,
DOI : 10.1172/JCI116343
Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti-RNA Polymerase III Autoantibodies, Arthritis & Rheumatology, vol.32, issue.4, pp.1045-52, 2015. ,
DOI : 10.1002/anr.1780320911
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38994/pdf
Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen, Arthritis Research & Therapy, vol.7, issue.3, pp.704-717, 1455. ,
DOI : 10.1186/ar1729
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients, Arthritis Research & Therapy, vol.11, issue.1, p.10, 1186. ,
DOI : 10.1186/ar2614
URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar2614?site=arthritis-research.biomedcentral.com
Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects, Autoimmunity, vol.35, issue.8, pp.542-51, 2015. ,
DOI : 10.1186/s13075-015-0573-x
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study, Annals of the Rheumatic Diseases, vol.67, issue.9, pp.1282-6073981, 2007. ,
DOI : 10.1136/ard.2007.073981
Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects, Medicine, vol.95, issue.35, pp.95-4713, 2016. ,
DOI : 10.1097/MD.0000000000004713
URL : http://pdfs.journals.lww.com/md-journal/2016/08300/Single_specificity_anti_Ku_antibodies_in_an.68.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1504749048791;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddFRrD2hcIwdDP9eSnSkfs80IcAqYqdta1Zm+65IrmaA=;hash|/wvxohCTPz1UsvbDzKgVpg==
Long-term survival and follow-up of anti-Th/to antibody positive systemic sclerosis patients, Arthritis Rheumatol, vol.69, pp.1-4426, 2017. ,
Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension, Arthritis & Rheumatology, vol.64, issue.Suppl 86, pp.484-93, 2016. ,
DOI : 10.1111/j.1365-3083.2006.01770.x
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.39432/pdf
Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis, Clinical and Experimental Immunology, vol.38, issue.2, pp.383-390, 1999. ,
DOI : 10.1016/0092-8674(84)90551-8
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2249.1999.00961.x/pdf
Anti???fibrillarin antibodies in systemic sclerosis, Rheumatology, vol.40, issue.10, pp.1157-62, 2001. ,
DOI : 10.1002/art.1780310207
URL : https://academic.oup.com/rheumatology/article-pdf/40/10/1157/18094746/401157.pdf
Anti-U3 RNP autoantibodies in systemic sclerosis, Arthritis & Rheumatism, vol.48, issue.4, pp.1112-1120, 2009. ,
DOI : 10.1056/NEJM197502132920706
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.24409/pdf
Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis, Arthritis & Rheumatism, vol.83, issue.7, pp.1151-60, 1996. ,
DOI : 10.7326/0003-4819-119-10-199311150-00007
Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis, The Journal of Rheumatology, vol.38, issue.8, pp.1622-1652, 2011. ,
DOI : 10.3899/jrheum.110071
Latest update on the Ro/SS-A autoantibody system, Autoimmunity Reviews, vol.8, issue.7, pp.632-639, 2009. ,
DOI : 10.1016/j.autrev.2009.02.010
Detection of autoantibodies to nucleolar transcription factor NOR 90/hubf in sera of patients with rheumatic diseases, by recombinant autoantigen???based assays, Arthritis & Rheumatism, vol.140, issue.8, pp.1313-1321, 1996. ,
DOI : 10.1002/art.1780390808
Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients, Autoimmunity Highlights, vol.36, issue.1, pp.29-33, 2011. ,
DOI : 10.3899/jrheum.080806
The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis, Rheumatology, vol.42, issue.4, pp.534-574, 2003. ,
DOI : 10.1093/rheumatology/keg170
Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning, Joint Bone Spine, vol.85, issue.2, pp.147-53, 2017. ,
DOI : 10.1016/j.jbspin.2017.11.006
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes, Arthritis Research & Therapy, vol.9, issue.4, pp.10-1186, 2007. ,
DOI : 10.1186/ar2276
URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar2276?site=arthritis-research.biomedcentral.com
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies, Medicine, vol.84, issue.4, pp.231-280, 2005. ,
DOI : 10.1097/01.md.0000173991.74008.b0
URL : http://pdfs.journals.lww.com/md-journal/2005/07000/Novel_Classification_of_Idiopathic_Inflammatory.5.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1503454446568;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddFRrD2hcIwdDP9eSnSkfs3Yq/IxEDZo0f4KRzkCU9Ds=;hash|+8auJX2Rt3eV8xg+yXGkXw==
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis The Netherlands, Neuromuscul Disord, vol.14, issue.5, pp.10-12337, 2003. ,
Evaluation and construction of diagnostic criteria for inclusion body myositis, Neurology, vol.83, issue.5, pp.426-459, 2014. ,
DOI : 10.1212/WNL.0000000000000642
URL : http://europepmc.org/articles/pmc4132572?pdf=render
The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome, Autoimmunity Reviews, vol.13, issue.9, pp.883-91, 2014. ,
DOI : 10.1016/j.autrev.2014.03.004
Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies, Chest, vol.138, issue.6, pp.1464-74, 2010. ,
DOI : 10.1378/chest.10-0180
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies, Autoimmunity, vol.3, issue.4, pp.233-411008916930600622884, 1080. ,
DOI : 10.1007/s11926-001-0039-9
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies, Rheumatology, vol.108, issue.11, pp.999-1007, 2017. ,
DOI : 10.1016/j.rmed.2014.09.003
Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity, Autoimmunity Reviews, vol.12, issue.2, pp.210-217, 2012. ,
DOI : 10.1016/j.autrev.2012.06.006
Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome, Autoimmunity Reviews, vol.11, issue.10, pp.739-784, 2012. ,
DOI : 10.1016/j.autrev.2012.01.006
URL : https://hal.archives-ouvertes.fr/hal-00872923
Anti???Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis & Rheumatism, vol.169, issue.9, pp.3125-3156, 2007. ,
DOI : 10.4049/jimmunol.169.12.7127
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.22865/pdf
Diagnosis and Management of Immune-Mediated Myopathies, Mayo Clinic Proceedings, vol.92, issue.5, pp.826-863, 2017. ,
DOI : 10.1016/j.mayocp.2016.12.025
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy, JAMA Neurology, vol.72, issue.9, pp.996-1003, 2015. ,
DOI : 10.1001/jamaneurol.2015.1207
URL : http://archneur.jamanetwork.com/data/journals/neur/934389/noi150031.pdf
Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies, Annals of Neurology, vol.1592, issue.suppl 1, pp.538-586, 2017. ,
DOI : 10.1016/S0167-4889(02)00318-X
myopathies, Neurology, vol.90, issue.6, pp.507-524, 2018. ,
DOI : 10.1212/WNL.0000000000004923
URL : https://hal.archives-ouvertes.fr/hal-01518320
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.10, pp.1038-1082, 2016. ,
DOI : 10.1002/art.34673
A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis & Rheumatism, vol.41, issue.9, pp.2757-66, 2010. ,
DOI : 10.1212/WNL.41.6.936
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.27572/pdf
Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy, Arthritis & Rheumatism, vol.41, issue.12, pp.4087-93, 2012. ,
DOI : 10.1002/acr.20035
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.34673/pdf
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective, Neuromuscular Disorders, vol.26, issue.11, pp.734-774, 2016. ,
DOI : 10.1016/j.nmd.2016.08.013
URL : http://researchrepository.murdoch.edu.au/id/eprint/33231/1/Needham1.pdf
Statin-Associated Autoimmune Myopathy, New England Journal of Medicine, vol.374, issue.7, pp.664-673, 2016. ,
DOI : 10.1056/NEJMra1515161
Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy, Arthritis & Rheumatism, vol.247, issue.7, pp.1961-71, 2011. ,
DOI : 10.1007/s004150050585
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.30344/pdf
Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle, Arthritis Care & Research, vol.24, issue.11, pp.263-70, 2017. ,
DOI : 10.1097/BOR.0b013e328358bd85
Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1??, Arthritis & Rheumatism, vol.146, issue.Suppl, pp.2954-62, 2013. ,
DOI : 10.1001/archdermatol.2009.328
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38093/pdf
Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy, Rheumatology, vol.46, issue.1, pp.25-33, 2007. ,
DOI : 10.1093/rheumatology/kel161
Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis, Arthritis & Rheumatism, vol.49, issue.Suppl, pp.523-555, 2012. ,
DOI : 10.1093/rheumatology/keq153
Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies, PLOS ONE, vol.27, issue.5, 2016. ,
DOI : 10.1371/journal.pone.0154746.s002
URL : https://doi.org/10.1371/journal.pone.0154746
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis, Arthritis Research & Therapy, vol.14, issue.2, pp.97-107, 2012. ,
DOI : 10.1186/ar3822
URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar3822?site=arthritis-research.biomedcentral.com
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis, Arthritis & Rheumatism, vol.103, issue.6, pp.1807-1821, 2009. ,
DOI : 10.1056/NEJM197502202920807
URL : http://europepmc.org/articles/pmc2701555?pdf=render
Clinical and Serologic Characterization of an Argentine Pediatric Myositis Cohort: Identification of a Novel Autoantibody (anti-MJ) to a 142-kDa Protein, The Journal of Rheumatology, vol.36, issue.11, pp.2547-51, 2009. ,
DOI : 10.3899/jrheum.090461
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A??retrospective study, Journal of the American Academy of Dermatology, vol.65, issue.1, pp.25-34, 2011. ,
DOI : 10.1016/j.jaad.2010.09.016
URL : http://europepmc.org/articles/pmc3167687?pdf=render
Utility of Anti-Melanoma Differentiation-Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta-Analysis, Arthritis Care & Research, vol.64, issue.8, pp.1316-1340, 2013. ,
DOI : 10.1002/art.34657
Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis, PLOS ONE, vol.8, issue.5, 2016. ,
DOI : 10.1371/journal.pone.0155381.s004
URL : https://doi.org/10.1371/journal.pone.0155381
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody, Rheumatology, vol.50, issue.3, pp.433-473, 2010. ,
DOI : 10.1002/pbc.21423
URL : https://academic.oup.com/rheumatology/article-pdf/49/3/433/17386711/kep375.pdf
Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission, Rheumatology, vol.81, issue.8, pp.800-804, 2012. ,
DOI : 10.1128/JVI.01360-06
URL : https://academic.oup.com/rheumatology/article-pdf/51/5/800/5112341/ker408.pdf
Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Rheumatology, vol.29, issue.11, pp.1563-70, 2012. ,
DOI : 10.1002/art.1780291109
Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort, Journal of Immunological Methods, vol.384, issue.1-2, pp.128-162, 2012. ,
DOI : 10.1016/j.jim.2012.07.019
Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1621-5097162, 2008. ,
DOI : 10.1136/ard.2008.097162
Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients, Autoimmunity, vol.43, issue.4, pp.279-84, 2013. ,
DOI : 10.1016/j.molcel.2011.05.020
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis, BMC Musculoskeletal Disorders, vol.49, issue.1, pp.223-233, 2010. ,
DOI : 10.1093/rheumatology/keq153
URL : https://bmcmusculoskeletdisord.biomedcentral.com/track/pdf/10.1186/1471-2474-11-223?site=bmcmusculoskeletdisord.biomedcentral.com
Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara, Arthritis Research & Therapy, vol.15, issue.2, pp.48-58, 2013. ,
DOI : 10.1186/ar3739
Inclusion body myositis, Current Opinion in Rheumatology, vol.29, issue.6, pp.632-640, 2017. ,
DOI : 10.1097/BOR.0000000000000436
Autoantibodies against a 43 KDa muscle protein in inclusion body myositis, PLoS One, vol.6, issue.5, 2011. ,
DOI : 10.1371/journal.pone.0020266
URL : https://doi.org/10.1371/journal.pone.0020266
Disease specificity of autoantibodies to cytosolic 5???-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Annals of the Rheumatic Diseases, vol.6, issue.4, pp.696-701, 2016. ,
DOI : 10.1371/journal.pone.0020266
URL : http://europepmc.org/articles/pmc4699257?pdf=render
Advances in serological diagnostics of inflammatory myopathies, Current Opinion in Neurology, vol.29, issue.5, pp.662-73, 2016. ,
DOI : 10.1097/WCO.0000000000000376
Rheumatoid arthritis, The Lancet, vol.388, issue.10055, pp.2023-2061, 2016. ,
DOI : 10.1016/S0140-6736(16)30173-8
URL : https://hal.archives-ouvertes.fr/hal-01558198
Predictors of infusion reactions during infliximab treatment in patients with arthritis, Arthritis Res Ther, vol.8, issue.4, pp.10-1186, 2006. ,
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study, Arthritis Research & Therapy, vol.13, issue.6, pp.10-1186, 2011. ,
DOI : 10.1136/ard.2009.121491
Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor, Saudi Medical Journal, vol.38, issue.9, pp.934-975, 2017. ,
DOI : 10.15537/smj.2017.9.20841
URL : https://www.smj.org.sa/index.php/smj/article/download/smj.2017.9.20841/10433
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis & Rheumatism, vol.143, issue.3, pp.315-339, 1988. ,
DOI : 10.1002/art.1780310302
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010. ,
DOI : 10.7326/0003-4819-124-8-199604150-00001
URL : https://hal.archives-ouvertes.fr/hal-01557559
To What Extent Is the Familial Risk of Rheumatoid Arthritis Explained by Established Rheumatoid Arthritis Risk Factors?, Arthritis & Rheumatology, vol.4, issue.2, pp.352-62, 2015. ,
DOI : 10.1371/journal.pone.0007969
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38927/pdf
Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden, Annals of the Rheumatic Diseases, vol.45, issue.1 ,
DOI : 10.1038/ng.2711
, Ann Rheum Dis, vol.75, issue.1, pp.183-192, 2016.
AN UNUSUAL PROTEIN COMPONENT OF HIGH MOLECULAR WEIGHT IN THE SERUM OF CERTAIN PATIENTS WITH RHEUMATOID ARTHRITIS, Journal of Experimental Medicine, vol.105, issue.5, pp.425-463, 1957. ,
DOI : 10.1084/jem.105.5.425
A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis, Autoimmune Dis, pp.2011-815038, 2011. ,
Clinical implications of IgA rheumatoid factor subclasses., Annals of the Rheumatic Diseases, vol.54, issue.7, pp.578-81, 1995. ,
DOI : 10.1136/ard.54.7.578
Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor, The Journal of Experimental Medicine, vol.12, issue.10, pp.1937-50, 2016. ,
DOI : 10.1155/2015/236451
URL : http://jem.rupress.org/content/213/10/1937.full.pdf
Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis, International Journal of Rheumatic Diseases, vol.50, issue.2, pp.379-86, 2013. ,
DOI : 10.1002/art.20018
URL : http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12129/pdf
Anti-keratin antibodies in rheumatoid arthritis., BMJ, vol.2, issue.6182, pp.97-106, 1979. ,
DOI : 10.1136/bmj.2.6182.97
URL : http://static.www.bmj.com/content/bmj/2/6182/97.full.pdf
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis, Arthritis Care & Research, vol.33, issue.11, pp.611472-83, 2009. ,
DOI : 10.1136/ard.2005.045229
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.24827/pdf
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies., Journal of Clinical Investigation, vol.101, issue.1, pp.273-81, 1316. ,
DOI : 10.1172/JCI1316
URL : http://www.jci.org/articles/view/1316/files/pdf
Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients, The Journal of Rheumatology, vol.41, issue.12, pp.2395-402, 2014. ,
DOI : 10.3899/jrheum.131375
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage, Annals of the Rheumatic Diseases, vol.62, issue.2, pp.120-126, 2003. ,
DOI : 10.1136/ard.62.2.120
URL : http://ard.bmj.com/content/annrheumdis/62/2/120.full.pdf
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study, Annals of the Rheumatic Diseases, vol.67, issue.2, pp.212-7068247, 2006. ,
DOI : 10.1136/ard.2006.068247
Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors, Arthritis & Rheumatism, vol.44, issue.2, pp.380-386, 2004. ,
DOI : 10.1136/ard.44.8.519
Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data, Rheumatology, vol.68, issue.1, pp.134-143, 2018. ,
DOI : 10.1002/art.39595